Journal of Diabetes最新文献

{"title":"Commentary on “Factors associated with diabetic foot ulcers and lower limb amputations in type 1 and type 2 diabetes supported by real-world data from the German/Austrian DPV registry”","authors":"Mostafa Javanian, Mohammad Barary, Soheil Ebrahimpour","doi":"10.1111/1753-0407.70035","DOIUrl":"https://doi.org/10.1111/1753-0407.70035","url":null,"abstract":"<p>We read with great interest the article “Factors associated with diabetic foot ulcers and lower limb amputations in type 1 and type 2 diabetes supported by real-world data from the German/Austrian DPV registry”,<span><sup>1</sup></span> published in your esteemed journal. The study provides an essential contribution to understanding the risk factors for diabetic foot ulcers (DFUs) and lower limb amputations, using real-world data from a significant cohort of adults with type 1 (T1D) and type 2 diabetes (T2D). The authors rightly highlight that sex, body height, and complications related to diabetes are associated with an elevated risk of DFUs in both T1D and T2D. Additionally, the potential for improved glycemic control and lipid management in T1D, alongside reduced smoking and alcohol consumption in T2D, is suggested as an intervention to mitigate these risks.</p><p>We commend the authors' comprehensive investigation. However, several methodological limitations warrant further discussion and consideration.</p><p>First, while the study incorporates key laboratory factors, selecting biomarkers appears somewhat restricted. Expanding the scope to include additional inflammatory markers such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), the systemic inflammation response index (SIRI), and the systemic immune-inflammation index (SII) would provide a more nuanced understanding of systemic inflammation's role in the development of DFUs and subsequent amputations.<span><sup>2, 3</sup></span> These markers have been shown to correlate with adverse outcomes in diabetic complications, yet they were not accounted for in this study. Including them would enhance the predictive model and potentially allow for more targeted interventions. Relevant comorbidities were either underexplored or omitted altogether. For example, cerebrovascular disease, malignancies, and psychological factors—each of which can significantly impact wound healing and overall morbidity—were not sufficiently addressed. A deeper exploration of these comorbidities could offer valuable insights into multifactorial risks associated with DFUs and amputations.</p><p>Third, a critical factor overlooked in the study is the duration of DFUs and their correlation with the likelihood of amputation. Wound chronicity is a well-established risk for poor outcomes, and incorporating this variable into the analysis would improve the understanding of which ulcers are most likely to lead to amputation. Additionally, the study could benefit from a more detailed classification of wounds based on their anatomical location (e.g., under the metatarsal heads, heel, or malleoli). Certain anatomical regions are more prone to complications, and this granularity could improve the precision of risk stratification.</p><p>Lastly, the role of foot deformities, particularly Charcot foot, in increasing the risk for DFUs and amp","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 12","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on the T1D Exchange Quality Improvement Collaborative Learning Session November 2024 abstracts.","authors":"Halis K Akturk, Osagie Ebekozien, Holly Hardison, Nicole Rioles, Stephanie Crossen","doi":"10.1111/1753-0407.70037","DOIUrl":"10.1111/1753-0407.70037","url":null,"abstract":"","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 12","pages":"e70037"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142890737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension approaches and recent SGLT2i studies","authors":"Zachary Bloomgarden","doi":"10.1111/1753-0407.70034","DOIUrl":"https://doi.org/10.1111/1753-0407.70034","url":null,"abstract":"<p>Several recent studies remind us to more fully address hypertension, suggest potentially useful approaches, point out the particular benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i), and indicate other effects of these agents.</p><p>In a randomized controlled trial (RCT) of 12 821 hypertensive persons with type 2 diabetes (T2D) having cardiovascular disease (CVD), or chronic kidney disease (CKD), or with 2 or more CVD risk factors, assigned to systolic blood pressure (SBP) goals of 120 vs 140, SBP at 1 year was 121.6 vs 133.2 mmHg, respectively, with the composite endpoint of stroke, myocardial infarction, heart failure or CV death occurring 21% less frequently in those assigned to the lower SBP target. Stroke and new onset albuminuria were reduced 21% and 13%, respectively, and similar benefit was seen regardless of age, sex, prior CVD or CKD, HbA1c, or duration of diabetes or of hypertension.<span><sup>1</sup></span></p><p>In a meta-analysis of seven hypertension (HBP) trials lasting 3.1–4.7 years, comparing SBP goals of <130 versus ≥130 mmHg among 72 138 participants with a mean age of 62–68, achieveing an SBP of <130 mm Hg was associated with a reduction in major CVD risk by 22%, mortality by 11%, stroke by 26%, coronary heart disease (CHD), including myocardial infarction, by 17%, heart failure (HF) by 31%, and CV mortality by 27%. In four trials, randomization to SBP <120 versus <140 reduced CVD 18%, mortality 15%, stroke 19%, CHD 13%, HF 24%, and CV mortality 28%. Rates of hypotension, syncope, injurious falls, electrolyte abnormalities, and acute kidney injury were higher with lower BP targets, but these events remained infrequent, with the number needed to harm 508 for hypotension and 3222 for electrolyte abnormality. Subgroup outcomes were reported inconsistently, so that differences in outcome could not be ascertained by diabetes, age, or CVD risk.<span><sup>2</sup></span></p><p>Given these results, it is sobering to look at achieved levels of BP control. In the combined dataset from The National Health and Nutrition Examination Survey (NHANES) of 2017–2018 and 2019–2020, among 7328 persons age ≥18, 3129 had SBP ≥130 or diastolic BP (DBP) ≥80, of whom 58% were unaware of HBP. Only 825 had a history of HBP with SBP <130. Of those with known HBP, 18% had an SBP of 130–139 or DBP of 80–89 with low atherosclerotic cardiovascular disease (ASCVD) risk, meeting the criteria for lifestyle modification, but 82% met criteria for lifestyle plus additional medication, with 26% having a history of CVD, 21% having CVD, and 21% having diabetes. NHANES is designed to allow estimates of the US population, showing 120 million people in the United States with HBP, 35 million of whom meet the criteria for additional antihypertensive medication, which the authors suggest “may reflect the slow adoption of the updated guidelines.”<span><sup>3</sup></span></p><p>Similarly, analysis of NHANES 2021-2023 showed that 47.7% of adults","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 11","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteriophages and their potential for treatment of metabolic diseases","authors":"Youpeng Deng,&nbsp;Shouwei Jiang,&nbsp;Hanyu Duan,&nbsp;Haonan Shao,&nbsp;Yi Duan","doi":"10.1111/1753-0407.70024","DOIUrl":"https://doi.org/10.1111/1753-0407.70024","url":null,"abstract":"<p>Recent advances highlight the role of gut virome, particularly phageome, in metabolic disorders such as obesity, type 2 diabetes mellitus, metabolic dysfunction-associated fatty liver disease, and cardiovascular diseases, including hypertension, stroke, coronary heart disease, and hyperlipidemia. While alterations in gut bacteria are well-documented, emerging evidence suggests that changes in gut viruses also contribute to these disorders. Bacteriophages, the most abundant gut viruses, influence bacterial populations through their lytic and lysogenic cycles, potentially modulating the gut ecosystem and metabolic pathways. Phage therapy, previously overshadowed by antibiotics, is experiencing renewed interest due to rising antibiotic resistance. It offers a novel approach to precisely edit the gut microbiota, with promising applications in metabolic diseases. In this review, we summarize recent discoveries about gut virome in metabolic disease patients, review preclinical and clinical studies of phage therapy on metabolic diseases as well as the breakthroughs and currently faced problems and concerns.</p><p>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 11","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long noncoding RNAs and metabolic memory associated with continued progression of diabetic retinopathy","authors":"Jay Kumar,&nbsp;Pooja Malaviya,&nbsp;Renu A. Kowluru","doi":"10.1111/1753-0407.70009","DOIUrl":"https://doi.org/10.1111/1753-0407.70009","url":null,"abstract":"<p>Progression of diabetic retinopathy resists arrest even after institution of intensive glycemic control, suggesting a “metabolic memory” phenomenon, but the mechanism responsible for this phenomenon is still elusive. Gene expression and biological processes can also be regulated by long noncoding RNAs (LncRNAs), the RNAs with &gt;200 nucleotides and no open reading frame for translation, and several LncRNAs are aberrantly expressed in diabetes. Our aim was to identify retinal LncRNAs that fail to reverse after termination of hyperglycemia. Microarray analysis was performed on retinal RNA from streptozotocin-induced diabetic rats in poor glycemic control for 8 months, followed by in good glycemic control (blood glucose &gt;400 mg/dL), or for 4 months, with four additional months of good glycemic control (blood glucose &lt;150 mg/dL). Differentially expressed LncRNAs and mRNAs were identified through Volcano filtering, and their functions were predicted using gene ontology and pathway enrichment analyses. Compared with age-matched normal rats, rats in continuous poor glycemic control had &gt;1479 differentially expressed LncRNAs (710 downregulated, 769 upregulated), and among those, 511 common LncRNAs had similar expression in Diab and Rev groups (139 downregulated, 372 upregulated). Gene Ontology/pathway analysis identified limited LncRNAs in biological processes, but analysis based on biological processes/molecular function revealed &gt;350 genes with similar expression in Diab and Rev groups; these genes were mainly associated with stress response, cell death, mitochondrial damage and cytokine production. Thus, identifying retinal LncRNAs and their gene targets that do not benefit from termination of hyperglycemia have potential to serve as therapeutic targets to slow down the progression of diabetic retinopathy.</p><p>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 11","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142665908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcellular mass spectrometric detection unveils hyperglycemic memory in the diabetic heart","authors":"Jiabing Zhan,&nbsp;Yufei Zhou,&nbsp;Yifan Chen,&nbsp;Kunying Jin,&nbsp;Zhaoyang Chen,&nbsp;Chen Chen,&nbsp;Huaping Li,&nbsp;Dao Wen Wang","doi":"10.1111/1753-0407.70033","DOIUrl":"10.1111/1753-0407.70033","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Intensive glycemic control is insufficient to reduce the risk of heart failure in patients with diabetes mellitus. While the hyperglycemic memory in the diabetic cardiomyopathy has been well documented, its underlying mechanisms are not fully understood. The present study tried to investigate whether the dysregulated proteins/biological pathways, which persistently altered in diabetic hearts during normoglycemia, participate in the hyperglycemic memory.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Hearts of streptozotocin-induced diabetic mice, with or without intensive glycemic control using slow-release insulin implants, were collected. Proteins from total heart samples and subcellular fractions were assessed by mass spectrometry, Western blotting, and KEGG pathway enrichment analysis. mRNA sequencing was used to determine whether the persistently altered proteins were regulated at the transcriptional or post-transcriptional level.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Western blot validation of several proteins with high pathophysiological importance, including MYH7, HMGCS2, PDK4, and BDH1, indicated that mass spectrometry was able to qualitatively, but not quantitatively, reflect the fold changes of certain proteins in diabetes. Pathway analysis revealed that the peroxisome, PPAR pathway, and fatty acid metabolism could be efficiently rescued by glycemic control. However, dysregulation of oxidative phosphorylation and reactive oxygen species persisted even after normalization of hyperglycemia. Notably, mRNA sequencing revealed that dysregulated proteins in the oxidative phosphorylation pathway were not accompanied by coordinated changes in mRNA levels, indicating post-transcriptional regulation. Moreover, literature review and bioinformatics analysis suggested that hyperglycemia-induced persistent alterations of miRNAs targeted genes from the persistently dysregulated oxidative phosphorylation pathway, whereas, oxidative phosphorylation dysfunction-induced ROS regulated miRNA expression, which thereby might sustained the dysregulation of miRNAs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Glycemic control cannot rescue hyperglycemia-induced alterations of subcellular proteins in the diabetic heart, and persistently altered proteins are involved in multiple functional pathways, including oxidative phosphorylation. These findings might provide novel insights into hyperglycemic memory in diabetic cardiomyopathy.&lt;/p&gt;\u0000 \u0000 &lt;div&gt;\u0000 &lt;figure&gt;\u0000 ","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 11","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural and functional alterations of the hippocampal subfields in T2DM with mild cognitive impairment and insulin resistance: A prospective study","authors":"Chen Yang,&nbsp;Huiyan Zhang,&nbsp;Zihan Ma,&nbsp;Yanjun Fan,&nbsp;Yanan Xu,&nbsp;Jian Tan,&nbsp;Jing Tian,&nbsp;Jiancang Cao,&nbsp;Wenwen Zhang,&nbsp;Gang Huang,&nbsp;Lianping Zhao","doi":"10.1111/1753-0407.70029","DOIUrl":"10.1111/1753-0407.70029","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance (IR) and is often accompanied by mild cognitive impairment (MCI). The detrimental effects of T2DM and IR on the hippocampus have been extensively demonstrated. Few studies have examined the effects of IR on structure and function of hippocampal subfields in T2DM-MCI patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A total of 104 T2DM patients were recruited in this prospective study and divided into four groups (T2DM-MCI-higherIR, <i>n</i> = 17; T2DM-MCI-lowerIR, <i>n</i> = 32; T2DM-nonMCI-higherIR, <i>n</i> = 19; T2DM-nonMCI-lowerIR, <i>n</i> = 36). Structure and function MRI data were captured. Clinical variables and neuropsychological scores were determined for all participants. Hippocampal subfield volume and functional connectivity were compared among four groups. Partial correlation analysis was performed between imaging indicators, clinical variables, and neuropsychological scores in all patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>T2DM-MCI-higher IR group had the smallest volumes of bilateral hippocampal tail, right subiculum-body, right GC-ML-DG-body, and right CA4-body. IR in right hippocampal tail, right subiculum-body, and right GC-ML-DG-body exerted main effect. Furthermore, elevated functional connectivity was found between right subiculum-body and bilateral dorsolateral prefrontal cortex and right anterior cingulate–medial prefrontal cortex. Hippocampal subfield volume positively correlates with total cholesterol and triglycerides and negatively correlates with fasting insulin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The present study found that T2DM-MCI patients have structural and functional alterations in hippocampal subfields, and IR is a negative factor influencing the alteration of hippocampal subfields volume. These findings support the importance of IR in T2DM-MCI patients and might be potential neuroimaging biomarkers of cerebral impairment in T2DM-MCI patients.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 11","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of maternal serum ferritin levels across gestation with gestational diabetes mellitus: A longitudinal cohort study","authors":"Huiqin Mo,&nbsp;Jingna Wen,&nbsp;Cuicui Qu,&nbsp;Xiaohua Liu","doi":"10.1111/1753-0407.70027","DOIUrl":"10.1111/1753-0407.70027","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The longitudinal changes in maternal serum ferritin (SF) levels across gestation, which indirectly reflect iron supplementation, have not been extensively investigated in relation to gestational diabetes mellitus (GDM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study at a tertiary maternal hospital in Shanghai. Women with SF concentration measurements at 8.0–13.6 weeks' gestation (GW), 29.0–31.6 GW, and an oral glucose tolerance test (OGTT) at 24–28 GW were included. We utilized logistic regression analysis to assess GDM association with maternal SF levels and longitudinal changes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 17 560 women, with 2160 (12.3%) participants diagnosed with GDM. Adjusted odds ratios (ORs) (95% confidence intervals [CIs]) for GDM across increasing quartiles of SF concentrations at 8.0–13.6 GW were 1.00 (reference), 1.139 (95% CI: 1.012–1.283), 1.093 (95% CI: 0.969–1.233), and 1.248 (95% CI: 1.111–1.403). Similarly, at 29.0–31.6 GW, increasing quartiles of SF concentrations were associated with higher adjusted ORs for GDM: 1.00 (reference), 1.165 (95% CI: 1.029–1.320), 1.335 (95% CI: 1.184–1.505), and 1.428 (95% CI: 1.268–1.607). Pregnant women with higher SF levels (upper 25th percentile) at 8.0–13.6 GW had a reduced GDM risk if their SF levels decreased to the lower 25th percentile at 29.0–31.6 GW. Conversely, the subgroup with higher SF levels (upper 25th percentile) at both time points had the highest incidence rate of GDM (15.3%, 1.235 [95% CI: 1.087–1.404]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Maternal SF levels independently and positively associated with GDM risk during early and late gestational stages. Considering the increased GDM risk, routine iron supplementation for iron-replete women is questionable.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 11","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences of visceral fat with cardiac structure and function in type 2 diabetes: A cross-sectional study","authors":"Chen Rui-hua,&nbsp;Lin Yi,&nbsp;Xu Huan-bai,&nbsp;Wang Yu-fan,&nbsp;Peng Yong-de","doi":"10.1111/1753-0407.70023","DOIUrl":"10.1111/1753-0407.70023","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The aim of this study is to analyze the associations among fat distribution, left ventricular (LV) structure, and function in T2DM patients and further assess the sex differences among them.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two thousand and one hundred seven T2DM patients were enrolled to this study. Patients' height, weight, BMI, visceral fat area (VFA), baPWV, parameters of cardiac structure and function, and clinical biochemical indicators were measured and collected.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were significant differences between male and female T2DM patients in age, duration of diabetes, complication ratio of hypertension and dyslipidemia, smoking history, visceral fat, baPWV, and ventricular structure and function (<i>p</i> &lt; 0.05). Compared with the Q1 group, female patients in the highest quartile (Q4) of VFA had a decreased LVEF and significantly increased baPWV (<i>p</i> &lt; 0.05), whereas no such changes were found in males. The correlation analysis showed that LVEF in male patients was negatively correlated with hypertension history, using of CCBs, GLP-1RA, lipid-lowering medications, BMI, WC, WHR, FPG, FC-P, HbA1c, GA, HOMA-IR, Cr, and baPWV, while the LVEF in female patients was negatively correlated with VFA, VSR, VFA/BMI, VFA/H², VFA/weight in females (<i>p</i> &lt; 0.05). LVMI was positively associated with diabetes duration, age, hypertension history, WC, WHR, VFA, SFA, VFA/BMI, VFA/H², VFA/weight, and baPWV in both males and females. Multivariable-adjusted linear regression analysis showed that VFA was independently associated with LVEF (<i>β</i> = − 0.096, <i>p</i> = 0.010), LVMI (<i>β</i> = 0.083, <i>p</i> = 0.038), and baPWV (<i>β</i> = 0.120, <i>p</i> = 0.003) in females.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Values of VFA were independently associated with LVEF, LVMI, and baPWV in women, but not in men, in patients with T2DM.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 11","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics, treatment, and treatment switch after molecular-genetic classification in individuals with maturity-onset diabetes of the young: Insights from the multicenter real-world DPV registry","authors":"Stefanie Lanzinger,&nbsp;Katharina Laubner,&nbsp;Katharina Warncke,&nbsp;Julia K. Mader,&nbsp;Sebastian Kummer,&nbsp;Claudia Boettcher,&nbsp;Torben Biester,&nbsp;Angela Galler,&nbsp;Daniela Klose,&nbsp;Reinhard W. Holl","doi":"10.1111/1753-0407.70028","DOIUrl":"10.1111/1753-0407.70028","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Individuals with maturity-onset diabetes of the young (MODY) are often misdiagnosed as type 1 or type 2 diabetes and receive inappropriate care. We aimed to investigate the characteristics and treatment of all MODY types in a multicenter, real-world setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Individuals with MODY from the diabetes prospective follow-up (DPV) registry were studied. We compared clinical parameters during the first year of diabetes and the most recent treatment year after MODY diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1640 individuals were identified with <i>GCK</i>-MODY (<i>n</i> = 941) and <i>HNF1A</i>-MODY (<i>n</i> = 417) as the most frequent types. Among these, 912 individuals were available with information during the first and the most recent treatment year (median duration of follow-up: 4.2 years [2.6–6.6]). Positive beta cell autoantibodies were present in 20.6% (15.2% IAA). Median age at diagnosis ranged from 9.9 years in <i>GCK</i>-MODY (Q1–Q3: 6.2–13.1 years) and <i>INS</i>-MODY (2.7–13.7 years) to 14.3 years (5.0–17.1) in <i>KCNJ11</i>-MODY. Frequency of oral antidiabetic agents (OAD) use increased and insulin decreased in <i>HNF4A</i>-MODY (OAD: 18% to 39%, insulin: 34% to 23%) and in <i>HNF1A</i>-MODY (OAD: 18% to 31%, insulin: 35% to 25%). <i>ABCC8</i>-MODY was characterized by a decrement in nonpharmacological treatment (26% to 16%) and “insulin only” treatment (53% to 42%), while the proportion of individuals treated with OAD but no insulin increased from 0% to 21%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our results indicate that some teams caring for individuals with MODY are hesitant with regard to current recommendations. Registries are an essential source of information and provide a basis for discussing treatment guidelines for MODY.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 11","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}